Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Motor and sensory neuropathy due to myelin infolding and paranodal damage in a transgenic mouse model of Charcot-Marie-Tooth disease type 1C.

Human molecular genetics | 2013

Charcot-Marie-Tooth disease type 1C (CMT1C) is a dominantly inherited motor and sensory neuropathy. Despite human genetic evidence linking missense mutations in SIMPLE to CMT1C, the in vivo role of CMT1C-linked SIMPLE mutations remains undetermined. To investigate the molecular mechanism underlying CMT1C pathogenesis, we generated transgenic mice expressing either wild-type or CMT1C-linked W116G human SIMPLE. Mice expressing mutant, but not wild type, SIMPLE develop a late-onset motor and sensory neuropathy that recapitulates key clinical features of CMT1C disease. SIMPLE mutant mice exhibit motor and sensory behavioral impairments accompanied by decreased motor and sensory nerve conduction velocity and reduced compound muscle action potential amplitude. This neuropathy phenotype is associated with focally infolded myelin loops that protrude into the axons at paranodal regions and near Schmidt-Lanterman incisures of peripheral nerves. We find that myelin infolding is often linked to constricted axons with signs of impaired axonal transport and to paranodal defects and abnormal organization of the node of Ranvier. Our findings support that SIMPLE mutation disrupts myelin homeostasis and causes peripheral neuropathy via a combination of toxic gain-of-function and dominant-negative mechanisms. The results from this study suggest that myelin infolding and paranodal damage may represent pathogenic precursors preceding demyelination and axonal degeneration in CMT1C patients.

Pubmed ID: 23359569 RIS Download

Research resources used in this publication

None found

Additional research tools detected in this publication

None found

Antibodies used in this publication

Associated grants

  • Agency: NINDS NIH HHS, United States
    Id: NS055077
  • Agency: NIEHS NIH HHS, United States
    Id: ES015813
  • Agency: NIA NIH HHS, United States
    Id: R01 AG034126
  • Agency: NIEHS NIH HHS, United States
    Id: R01 ES015813
  • Agency: NIA NIH HHS, United States
    Id: AG034126
  • Agency: NIGMS NIH HHS, United States
    Id: R01 GM103613
  • Agency: NIGMS NIH HHS, United States
    Id: GM103613
  • Agency: NINDS NIH HHS, United States
    Id: (NS063501
  • Agency: NINDS NIH HHS, United States
    Id: P30 NS055077
  • Agency: NIGMS NIH HHS, United States
    Id: T32 GM008169
  • Agency: NINDS NIH HHS, United States
    Id: F30 NS063501

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Anti-Kv1.2 K+ Channel Antibody (antibody)

RRID:AB_2296313

This monoclonal targets Kv1.2 K+ channel

View all literature mentions